Targeting obesity subgroups

Both of the obesity therapeutics Orexigen Therapeutics Inc. is developing are oral, twice-daily combinations of approved drugs that include extended-release bupropion as one of their components. But the second component of each gives the two therapies different mechanisms of action that the company believes will be suited for different patient populations.

OREX presented full data from its Phase IIb trial of Empatic at the recent North American Association for the Study

Read the full 715 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE